Investigating how oncolytic viruses can change the immune environment in glioblastoma.
Oncolytic Virus Therapeutic Responses Occur from Changes in the Glioblastoma Immune Microenvironment
['FUNDING_R01'] · BRIGHAM AND WOMEN'S HOSPITAL · NIH-11063232
This study is looking at a new way to help people with glioblastoma, a tough brain tumor, by using a modified herpes virus to boost the immune system's ability to fight the tumor, especially in those who have had the herpes virus before.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BRIGHAM AND WOMEN'S HOSPITAL (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-11063232 on ClinicalTrials.gov |
What this research studies
This research focuses on glioblastoma, a highly aggressive brain tumor that is resistant to standard treatments. The study explores the use of oncolytic viruses, specifically a modified herpes simplex virus, to alter the tumor's immune microenvironment, making it more responsive to treatment. By analyzing patient responses, the research aims to understand how these viruses can stimulate the immune system to attack the tumor more effectively. Patients who have previously been exposed to the herpes virus may have a better response to this therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma, particularly those with a history of herpes simplex virus exposure.
Not a fit: Patients with glioblastoma who do not have any prior exposure to herpes simplex virus may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for glioblastoma, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Previous studies have shown promising results using oncolytic viruses in other cancers, indicating potential for success in glioblastoma as well.
Where this research is happening
BOSTON, UNITED STATES
- BRIGHAM AND WOMEN'S HOSPITAL — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CHIOCCA, E. ANTONIO — BRIGHAM AND WOMEN'S HOSPITAL
- Study coordinator: CHIOCCA, E. ANTONIO
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer, anti-cancer immunotherapy, anticancer immunotherapy, Autoimmune Diseases, autoimmune disorder